'Timing couldn't be better': An ex-generics maker goes SPAC route with blank check intended for sports market
Dave Mehalick originally planned for his company to be a generics maker with five drugs in the hopper. But quickly after founding Coeptis Therapeutics in 2017, he realized that area of the pharmaceutical market was “really becoming a race to the bottom.”
So, he pivoted. The little-known Pittsburgh-area biotech raised a couple million dollars over the years from private investors, went public on the OTC Pink market and linked arms with VyGen-Bio, the Karolinska Institutet and Statera Biopharma to become an oncology cell therapy developer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.